news

Oct 10, 2024
Oct 8, 2024
Oct 2, 2024
Linkedin-in

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. LPCN 1154 for Postpartum

Recent

Press

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Read More

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Read More

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Read More

Focus on enhancing health

We are pioneers of developing innovative drug products targeting significant unmet medical needs.